Skandinaviska Enskilda Banken (SEB)’s Protagonist Therapeutics PTGX Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-205,574	Closed	-$18M	–	570
2025 Q4	$18M	Buy	205,574 +126,778	+161%	+$10.4M	0.07%	193
2025 Q3	$5.23M	Sell	78,796 -3,954	-5%	-$225K	0.02%	408
2025 Q2	$4.57M	Sell	82,750 -166,200	-67%	-$7.98M	0.02%	439
2025 Q1	$12M	Sell	248,950 -61,700	-20%	-$2.59M	0.06%	247
2024 Q4	$12M	Buy	310,650 +80,536	+35%	+$3.51M	0.05%	247
2024 Q3	$10.4M	Buy	230,114 +211,200	+1,117%	+$8.53M	0.05%	270
2024 Q2	$655K	Hold	18,914	–	–	﹤0.01%	671
2024 Q1	$547K	Hold	18,914	–	–	﹤0.01%	703
2023 Q4	$434K	Hold	18,914	–	–	﹤0.01%	786
2023 Q3	$315K	Hold	18,914	–	–	﹤0.01%	802
2023 Q2	$522K	Buy	+18,914	New	+$473K	﹤0.01%	786
2022 Q4	–	Sell	-48,977	Closed	-$413K	–	898
2022 Q3	$413K	Hold	48,977	–	–	﹤0.01%	767
2022 Q2	$387K	Hold	48,977	–	–	﹤0.01%	839
2022 Q1	$1.16M	Buy	48,977 +10,673	+28%	+$301K	0.01%	739
2021 Q4	$1.31M	Hold	38,304	–	–	0.01%	733
2021 Q3	$679K	Buy	38,304 +7,676	+25%	+$327K	﹤0.01%	840
2021 Q2	$1.38M	Buy	+30,628	New	+$1.01M	0.01%	757

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s PTGX Position: Q1 2026 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Protagonist Therapeutics (PTGX) in Q1 2026, closing a stake of 205,574 shares — an estimated $18M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in PTGX in Q2 2021 and held it in 17 quarters. The position peaked at $18M in Q4 2025. 320 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

Skandinaviska Enskilda Banken (SEB) reported no remaining Protagonist Therapeutics position as of Q1 2026 after selling out during the quarter.
Skandinaviska Enskilda Banken (SEB) sold 205,574 Protagonist Therapeutics shares in Q1 2026, an estimated $18M.
Skandinaviska Enskilda Banken (SEB) first reported a position in Protagonist Therapeutics in Q2 2021 and held it in 17 quarters.
Skandinaviska Enskilda Banken (SEB)'s Protagonist Therapeutics position peaked at $18M in Q4 2025.
320 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q1 2026, filed 15 May 2026.